Precision Meets Protocol: Implementing Biomarkers Into a Structured Nodule Management Care Pathway
| Estimated time to read:
The following content is part of a paid sponsorship and is not an endorsement by CHEST nor does it reflect the views or opinions of CHEST.
CHEST 2026
Exhibit Hall, Learning Theater 4
Monday, October 19
10:15 a.m. – 11:00 a.m.
Biomarker-driven risk stratification is emerging as a critical complement to guideline-based lung nodule management. While the question is no longer whether biomarkers belong in the diagnostic pathway, clinicians continue to evaluate where biomarker testing can provide the greatest value in clinical decision-making.
Join Dr. Sonali Sethi, board-certified Interventional Pulmonologist, for a practical discussion on how clinicians are incorporating biomarker-informed risk assessment into real-world lung nodule management. Through clinical evidence, case-based insights, and implementation considerations, this session will explore how personalized malignancy risk assessment can support decision-making at the point of care.
Learning Objectives:
- Learn how blood-based biomarker testing aligns with and complements existing approaches to indeterminate lung nodule management.
- Review the clinical evidence supporting biomarker-informed risk reclassification across the spectrum of post-test malignancy risk.
- Explore when and where biomarker testing may provide the greatest diagnostic and decision-making value within a multidisciplinary care pathway.
Secure your seat today!
The Biodesix clinical team will also be at Booth #745 all week for in-depth conversations and a closer look at how Nodify Lung testing fits into your workflow.
This is a non-CME event and does not qualify for CME or CE, or MOC credit. This event is not part of the official CHEST Annual Meeting 2026 conference sessions. This event is not an endorsement by CHEST and does not reflect the views or opinions of CHEST.
